JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $185 from $177 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $155 from $140 at Truist
- Neurocrine price target raised to $155 from $150 at Deutsche Bank
- Neurocrine treatment of Friedreich ataxia granted orphan designation
- Neurocrine price target raised to $246 from $242 at Citi
- Neurocrine price target raised to $207 from $190 at Piper Sandler